Drawing from PSGs 2025 Trends in Drug Benefit Design Report, this webinar provides essential insights for benefits professionals navigating the complex landscape of GLP-1 coverage decisions
We continue to find new ways to keep pace with this communitys growth and provide the most comprehensive cancer care to this community
Poly-agonists An exciting recent pharmaceutical strategy to the treatment of obesity and T2DM has been the development of hybrid peptides that activate more than one receptor to generate an effect (202)
Fiber intake: Aim for 25-35 grams of fiber daily from a mix of soluble and insoluble sources
Now, with the FDA's recent approval of Foundayo (orforglipron), Eli Lilly has introduced something that could shift the entire landscape: an oral GLP-1 receptor agonist that you simply swallow like any other daily pill
In a combined analysis of subcutaneous (SUSTAIN-6) and oral [PIONEER 6 (NCT02692716)] T2DM CVOTs, semaglutide consistently reduced MACE risk versus placebo across all eGFR and urinary albumin:creatinine ratio (UACR) subgroups [58] Additionally, semaglutide (SELECT) reduced MACE in participants with overweight/obesity and baseline CVD but no T2DM [48]
